Released: · Last reviewed:
A 503A pharmacy compounds medicines for individual patients under state board oversight, while a 503B outsourcing facility registers with the FDA, follows federal manufacturing standards and can make batches without patient-specific prescriptions; as of November 2026, the FDA has proposed keeping semaglutide off the 503B bulks list. That proposal (91 FR 23431, announced April 30, 2026) had no final decision as of October 15, 2026. NexLife's plan pages name three state-licensed 503A pharmacies, and you can check any pharmacy's license with its state board.
Compounded semaglutide reaches patients through one of two regulated pharmacy pathways under the U.S. Federal Food, Drug, and Cosmetic Act: Section 503A licensed compounding pharmacies and Section 503B FDA-registered outsourcing facilities.
Section 503A: licensed by state pharmacy boards. Compounds based on patient-specific prescriptions. Operates under USP <797> sterile compounding standards. Bulk compounding for office use is restricted. Section 503B: registered with FDA. Operates under FDA cGMP standards (21 CFR 211). Permitted to compound in larger volumes for distribution to facilities without patient-specific prescriptions. NexLife uses both pathways and discloses both publicly. Many competitors disclose neither.
NexLife is structured around clinical best practices for semaglutide. See full NexLife review.
Compounded semaglutide · clinician oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000
Citations supporting clinical and regulatory statements on this page. External links open in a new tab.